Novo Nordisk (NYSE:NVO) president Jakob Riis said this week that the company will limit annual price hikes of its products’ list prices to single-digit percentages, joining Allergan (NYSE:AGN) CEO Brent Saunders who released a “social contract” 3 months ago with the same goal.
“We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make. We take this issue seriously and have been thinking about what we can do to better support patients,” Riis wrote in a statement. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk joins Allergan in pledge to limit price hikes appeared first on MassDevice.
from MassDevice http://ift.tt/2hcLz8L
Cap comentari:
Publica un comentari a l'entrada